Key result
Serum fibroblast growth factor 21 levels were an independent predictor of aortic stiffness in patients with type 2 diabetes mellitus (OR 1.005; 95% CI 1.002-1.009; p=0.002).
Why the study?
Aortic stiffness is associated with cardiovascular disease in T2DM, but the relationship between serum fibroblast growth factor 21 and aortic stiffness in these patients required evaluation.
Are serum FGF-21 levels associated with aortic stiffness in patients with type 2 diabetes mellitus?
Cross-Sectional (n=130)
Are serum FGF-21 levels associated with aortic stiffness in patients with type 2 diabetes mellitus?
Odds Ratio: 1.005 (95% CI 1.002–1.009)
p-value: p=0.002
Higher serum FGF-21 levels are independently associated with increased aortic stiffness in patients with type 2 diabetes mellitus, suggesting its potential as a biomarker for vascular risk.
May inform vascular risk stratification in T2DM; leaves open causal role and need for prospective validation.
Aortic stiffness (AS), assessed using carotid–femoral pulse wave velocity (cfPWV), is associated with cardiovascular disease in type 2 diabetes mellitus (T2DM). The relationship between serum fibroblast growth factor 21 (FGF-21) and AS in T2DM patients was evaluated. Fasting serum FGF-21 levels of 130 T2DM patients were measured using an enzyme immunoassay kit. A validated tonometry system was used to measure cfPWV (>10 m/s indicated AS). Of these T2DM patients, 34.6% were defined as the AS group. T2DM patients with AS were older; exhibited higher systolic blood pressure, diastolic blood pressure, and body fat mass; higher triglyceride, fasting glucose, glycosylated hemoglobin, and creatinine levels; higher urine albumin-to-creatinine ratios and serum FGF-21 levels; and lower estimated glomerular filtration rates. The FGF-21 level (odds ratio = 1.005, 95% confidence interval: 1.002–1.009, p = 0.002) as well as systolic blood pressure was an independent predictor of AS and positively correlated to cfPWV values (β = 0.369, p < 0.001) in T2DM patients. For T2DM patients, serum FGF-21 level could be a predictor for AS.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2021) conducted a cross-sectional in Type 2 Diabetes Mellitus (n=130). Serum fibroblast growth factor 21 (FGF-21) level was evaluated on Aortic stiffness (carotid-femoral pulse wave velocity >10 m/s) (OR 1.005, 95% CI 1.002-1.009, p=0.002). Serum fibroblast growth factor 21 levels were an independent predictor of aortic stiffness in patients with type 2 diabetes mellitus (OR 1.005; 95% CI 1.002-1.009; p=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: